TGEN Drug Development and Flagship Biosciences offer combined services for pharmaceutical and biotech clients in oncology and pathology
Flagstaff, AZ — 17 January 2011 — Two Arizona drug development firms announced today a partnership for oncology pharmaceutical services.
Oncology product development is dependent on an accurate and quantitative assessment of the local tumor environment, which is assessed by pathology. Firms frequently require an integrated combination of molecular testing and profiling techniques along with pathology analysis. TGEN’s Drug Development (TD2) Services has a complete set of molecular profiling tools available to their pharmaceutical clients. Flagship Biosciences is a digital pathology company with quantitative approaches to multiplexed biomarker analysis in tissue. Clients can now access both molecular testing with quantitative pathology analysis.
“The local tumor environment is key to understanding efficacy and toxicity of oncology compounds in both preclinical and clinical trials,” said Dr. Daniel Van Hoff, CMO of TGEN. “Working with Flagship Biosciences brings a wealth of pathology knowledge in pharmaceutical product development, experience in difficult histology analysis challenges like the epithelial-mesenchymal transition, and quantitative multiplexing in tissue.”
“TGEN is the world-leader in novel approaches to oncology and oncology clinical trials,” said Dr. David Young, President of Flagship Biosciences. “It is exciting to be partnering with TGEN, and combining our quantitative pathology with TGEN’s oncology and molecular tumor profiling expertise. TGENs leadership in novel approaches to oncology clinical trials is an exciting match for digital pathology techniques and the promise of quantitative and virtual pathology analysis of patients and tumor response.”
“This partnership is a further demonstration of the emerging regional strength of Arizona for biotech product development,” said Dr. Robert Kellar, a board member of Flagship Biosciences. “Arizona is a unique resource for pharma, biotech, and device clients looking for the rapid application of new technology in development and clinical trials.
TD2 integrates world-class clinical and regulatory expertise with “-omic” science and provides unique drug development services aimed at minimizing the risk for clients in the Oncology drug development industry.
Flagship Biosciences is a pathologist-owned pharma services organization that utilized digital pathology to deliver quantitative tissue assessment in pharma and device development. Backed by a combined 60 years of pharmaceutical pathology experience, we have a worldclass team of pathology, image analysis, and companion diagnostics regulatory experts.
